摘要
目的:探讨门冬氨酸鸟氨酸预防肿瘤患者化疗性肝损伤的效果。方法:计算机检索The Cochrane Library、Clinical Trials.gov、Medline、Embase、EBSCO、中国知网(CNKI)、万方数据库(Wanfang Data)、维普数据库(VIP Data)和中国生物医学数据库(CBM),获得相关的随机对照试验(RCTs),进行数据提取和质量评价,使用RevMan 5.3软件进行Meta分析。结果:共纳入7项RCTs,共计609例患者;与对照组相比,门冬氨酸鸟氨酸可显著降低肿瘤患者化疗性肝损率[RR=0.33,95%CI(0.23,0.47),P<0.000 01],对ALT降低值[MD=–65.88,95%CI(–75.81,–55.95),P<0.000 01]、AST降低值[MD=–54.80,95%CI(–57.28,–52.32),P<0.000 01]和T-Bil降低值[MD=–50.28,95%CI(–60.35,–40.21),P<0.000 01]也具有显著性差异。结论:基于当前的临床证据,门冬氨酸鸟氨酸可有效预防肿瘤患者化疗性肝损伤,但研究间仍存在一定的异质性,故需更多高水平、大样本、多中心的随机对照试验予以验证。
Objective： To investigate the protective effect of L-ornithine-L-aspartate on chemotherapy induced liver injury in cancer patients. Methods： Randomized controlled trials were searched by computer in the Cochrane Library, Clinical Trials.gov, Medline, Embase, EBSCO, CNKI, Wanfang database, VIP database, and Chinese biomedical database （CBM）. Data extraction and quality evaluation were carried out based on the Cochrane Handbook 5.1. Meta-analysis was performed by RevMan 5.3 software. Results： Totally seven RCTs, 609 patients were included. The results of Meta-analysis showed that compared with control group, L-ornithine-L-aspartate could signifcantly reduce incidences of liver damage [RR = 0.33, 95%CI （0.23, 0.47）, P 〈 0.000 01], decrease ALT [MD = – 65.88, 95%CI （– 75.81, – 55.95）, P 〈 0.000 01], AST [MD = – 54.80, 95%CI （– 57.28, – 52.32）, P 〈 0.000 01] and T-Bil [MD = – 50.28, 95%CI （– 60.35, – 40.21）, P 〈 0.000 01]. Conclusion： Based on the current clinical evidence, L-ornithine-L-aspartate showed signifcant protective effect on chemotherapy induced liver injury in cancer patients. But there is still certain heterogeneity in different studies. Therefore more high quality, large scale, multicenter, randomized controlled trials are needed to be performed to verify this conclusion.
出处
《中国药物应用与监测》
CAS
2017年第3期131-134,共4页
Chinese Journal of Drug Application and Monitoring
基金
宁波市鄞州区科技计划项目(2016年第一批-29)
